A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
Status:
Completed
Trial end date:
2017-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a novel diagnostic Positron Emission Tomography (PET)
imaging agent for safety and biodistribution. The agent binds Prostate Specific Membrane
Antigen (PSMA) and is designed to detect prostate tumors.